CARRARA, LETIZIA
CARRARA, LETIZIA
DIPARTIMENTO DI INGEGNERIA INDUSTRIALE E DELL'INFORMAZIONE
Current mathematical models for cancer drug discovery
2017-01-01 Carrara, Letizia; Lavezzi, SILVIA MARIA; Borella, Elisa; DE NICOLAO, Giuseppe; Magni, Paolo; Poggesi, Italo
Does the modelling strategy make the difference in pharmacometrics? Some examples in oncology and infectious diseases
2018-01-26 Carrara, Letizia
Ethambutol disposition in humans: Challenges and limitations of whole-body physiologically-based pharmacokinetic modelling in early drug development
2020-01-01 Carrara, L.; Magni, P.; Teutonico, D.; Pasotti, L.; Della Pasqua, O.; Kloprogge, F.
Evaluation of software tools for Bayesian estimation on population models with count and continuous data
2015-01-01 Borella, Elisa; Carrara, Letizia; Lavezzi, SILVIA MARIA; Mezzalana, Enrica; Pasotti, Lorenzo; DE NICOLAO, Giuseppe; Magni, Paolo
Mathematical modeling of efficacy and safety for anticancer drugs clinical development
2018-01-01 Lavezzi, S. M.; Borella, E.; Carrara, L.; De Nicolao, G.; Magni, P.; Poggesi, I.
Methods and tools for multiscale modelling in Systems Pharmacology: a review
2016-01-01 Borella, Elisa; Carrara, Letizia; Lavezzi, SILVIA MARIA; Massaiu, Ilaria; Sauta, Elisabetta; Tosca, ELENA MARIA; Vitali, Francesca; Zucca, Susanna; Pasotti, Lorenzo; DE NICOLAO, Giuseppe; Magni, Paolo
Model Description Language (MDL) - a standard for model communication and interoperability
2016-01-01 Smith, Mk; Moodie, S; Bizzotto, R; Blaudez, E; Borella, Elisa; Carrara, Letizia; Chan, P; Chenel, M; Comets, E; Gieschke, R; Harling, K; Harnisch, L; Hartung, N; Hooker, A; Karlsson, Mo; Kaye, R; Kloft, C; Kokash, N; Lavielle, M; Magni, Paolo; Mari, A; Mentre, F; Muselle, C; Nordgren, R; Nyberg, H; Parra Guillen, Zp; Pasotti, Lorenzo; Rode Kristensen, N; Smith, G; Swat, Mj; Terranova, Nadia; Yvon, F; Holford, NICHOLAS HUGH GEORGE
Model description language (MDL): a standard for pharmacometric modelling and simulation
2017-01-01 Smith, Mk; Moodie, Sl; Bizzotto, R; Blaudez, E; Borella, E; Carrara, L; Chan, P; Chenel, M; Comets, E; Gieschke, R; Harling, K; Harnisch, L; Hartung, N; Hooker, A; Karlsson, Mo; Kaye, R; Kloft, C.; Kokash, N; Lavielle, M.; Magni, P; Mari, A; Mentré, F; Muselle, C; Nordgren, R; Nyberg, H; Parra-Guillén, Zp; Pasotti, L; Rode-Kristensen, N; Sardu, Ml; Smith, Gr; Swat, Mj; Terranova, N; Yngman, G; Yvon, F; Holford and on behalf of the DDMoRe consortium, N
Modelling the effect of Sunitinib given alone and in combination with CPT-11 on the tumor growth in xenografted mice
2015-01-01 Carrara, Letizia; Ribba, B.; Tod, M.; Wei, M.; You, B.; Freyer, G.; Magni, Paolo
Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations
2017-01-01 Pigatto, M. C.; Roman, R. M.; Carrara, Letizia; Buffon, A.; Magni, Paolo; Dalla Costa, T.
PK/PD modeling of tumor growth inhibition after etoposide administration in vitro and to tumor-bearing rats
2015-01-01 Pigatto, M. C.; Roman, R. M.; Carrara, Letizia; Magni, Paolo; Dalla Costa, T.
Which data are necessary to build a WB-PBPK model that accurately predicts exposure in the lung? A case study using Ethambutol for tuberculosis treatment
2017-01-01 Carrara, Letizia; Magni, Paolo; Teutonico, D.; Della Pasqua, O.; Kloprogge, F.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Current mathematical models for cancer drug discovery | 1-gen-2017 | Carrara, Letizia; Lavezzi, SILVIA MARIA; Borella, Elisa; DE NICOLAO, Giuseppe; Magni, Paolo; Poggesi, Italo | |
Does the modelling strategy make the difference in pharmacometrics? Some examples in oncology and infectious diseases | 26-gen-2018 | Carrara, Letizia | |
Ethambutol disposition in humans: Challenges and limitations of whole-body physiologically-based pharmacokinetic modelling in early drug development | 1-gen-2020 | Carrara, L.; Magni, P.; Teutonico, D.; Pasotti, L.; Della Pasqua, O.; Kloprogge, F. | |
Evaluation of software tools for Bayesian estimation on population models with count and continuous data | 1-gen-2015 | Borella, Elisa; Carrara, Letizia; Lavezzi, SILVIA MARIA; Mezzalana, Enrica; Pasotti, Lorenzo; DE NICOLAO, Giuseppe; Magni, Paolo | |
Mathematical modeling of efficacy and safety for anticancer drugs clinical development | 1-gen-2018 | Lavezzi, S. M.; Borella, E.; Carrara, L.; De Nicolao, G.; Magni, P.; Poggesi, I. | |
Methods and tools for multiscale modelling in Systems Pharmacology: a review | 1-gen-2016 | Borella, Elisa; Carrara, Letizia; Lavezzi, SILVIA MARIA; Massaiu, Ilaria; Sauta, Elisabetta; Tosca, ELENA MARIA; Vitali, Francesca; Zucca, Susanna; Pasotti, Lorenzo; DE NICOLAO, Giuseppe; Magni, Paolo | |
Model Description Language (MDL) - a standard for model communication and interoperability | 1-gen-2016 | Smith, Mk; Moodie, S; Bizzotto, R; Blaudez, E; Borella, Elisa; Carrara, Letizia; Chan, P; Chenel, M; Comets, E; Gieschke, R; Harling, K; Harnisch, L; Hartung, N; Hooker, A; Karlsson, Mo; Kaye, R; Kloft, C; Kokash, N; Lavielle, M; Magni, Paolo; Mari, A; Mentre, F; Muselle, C; Nordgren, R; Nyberg, H; Parra Guillen, Zp; Pasotti, Lorenzo; Rode Kristensen, N; Smith, G; Swat, Mj; Terranova, Nadia; Yvon, F; Holford, NICHOLAS HUGH GEORGE | |
Model description language (MDL): a standard for pharmacometric modelling and simulation | 1-gen-2017 | Smith, Mk; Moodie, Sl; Bizzotto, R; Blaudez, E; Borella, E; Carrara, L; Chan, P; Chenel, M; Comets, E; Gieschke, R; Harling, K; Harnisch, L; Hartung, N; Hooker, A; Karlsson, Mo; Kaye, R; Kloft, C.; Kokash, N; Lavielle, M.; Magni, P; Mari, A; Mentré, F; Muselle, C; Nordgren, R; Nyberg, H; Parra-Guillén, Zp; Pasotti, L; Rode-Kristensen, N; Sardu, Ml; Smith, Gr; Swat, Mj; Terranova, N; Yngman, G; Yvon, F; Holford and on behalf of the DDMoRe consortium, N | |
Modelling the effect of Sunitinib given alone and in combination with CPT-11 on the tumor growth in xenografted mice | 1-gen-2015 | Carrara, Letizia; Ribba, B.; Tod, M.; Wei, M.; You, B.; Freyer, G.; Magni, Paolo | |
Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations | 1-gen-2017 | Pigatto, M. C.; Roman, R. M.; Carrara, Letizia; Buffon, A.; Magni, Paolo; Dalla Costa, T. | |
PK/PD modeling of tumor growth inhibition after etoposide administration in vitro and to tumor-bearing rats | 1-gen-2015 | Pigatto, M. C.; Roman, R. M.; Carrara, Letizia; Magni, Paolo; Dalla Costa, T. | |
Which data are necessary to build a WB-PBPK model that accurately predicts exposure in the lung? A case study using Ethambutol for tuberculosis treatment | 1-gen-2017 | Carrara, Letizia; Magni, Paolo; Teutonico, D.; Della Pasqua, O.; Kloprogge, F. |